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Gender differences on methadone maintenance treatment
outcome among patients with opioid use disorder: A
systematic review
Objectives: The objective of this study was to review the
significant differences of MMT outcomes related to drug use
behavior, health status, and social behavioral functioning
between genders....




Plasma Concentrations of Pro-inflammatory Cytokine IL-
6 and Antiinflammatory Cytokine IL-10 in Short- and
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inflammatory cytokines. Objectives: This study examined
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The development and assessment of modified
Fagerstrom test for nicotine dependence scale among
Malaysian single electronic cigarette users
Background: The Fagerstrom test for nicotine dependence
(FTND) is the most widely used scale for assessing nicotine
dependence on conventional tobacco cigarettes (TCGs). But
the FTND does not e...




A bibliometric analysis of opioid in Malaysia
Opioid analgesics have been widely used for the treatment
of pain. In USA, it was reported an increase in opioid
prescribing is parallel with the increase of opioid use
disorders such as misuse, abuse...




Molecular docking study of naturally derived
flavonoids with antiapoptotic BCL-2 and BCL-XL
proteins toward ovarian cancer treatment
The naturally derived flavonoids are well known to have
anticarcinogenic effects. Flavonoids could be an alternative
strategy for ovarian cancer treatment, due to existing
platinum-based drugs are rep...
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   Abstract  
Background: Type 2 diabetes mellitus (T2DM) is a chronic disease where most of the patients usually need polytherapy.
This could affect their medication adherence (MA). However, other complex factors may also associate with MA, which
are important to identify. Aim: The purpose of this study was to evaluate the MA of patients with T2DM who received
polytherapy and to identify other factors that can affect the MA. Materials and Methods: This was a cross-sectional
study conducted in seven community health centers in Jakarta with HbA1C representing their MA level. Poor controlled
blood glucose with Hemoglobin A1C (HbA1C) of ≥7% is indicated to have low MA. All characteristics were collected to
identify factors that are potentially associated with low MA. The univariate analysis tests were used to analyze factors
that potentially associate with low MA. Multiple logistic regression analysis was performed in the factors to find their
relationship with low MA. Results: The study obtained 143 patients with a female dominance (67.8%) and mean ±
standard deviation (SD) age of 59.53 ± 9.251 years. Approximately 75.5% of the patients had low MA (HbA1C ≥ 7).
Univariate analysis found that duration of T2DM significantly (P = 0.047) related to MA, where patients with T2DM of
less than or equal to 5 years tended to have low MA. Logistic regression showed that patients with T2DM less than or
equal to 5 years (P = 0.015, odds ratio = 1.206, 95% confidence interval = 1.216–8.014) were associated with low MA.
Conclusion: Patients with the duration of T2DM less than or equal to 5 years surprisingly were susceptible to have low
MA. Low MA was not affected by polytherapy.
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   Introduction  
Diabetes mellitus (DM) is a metabolic disorder with a maximum number of patients. In 2017, the prevalence of diabetics
worldwide was 425 million, and it is estimated that in 2045, people with diabetes will reach 693 million. People with
diabetes in Indonesia ranks sixth in the world along with China, India, the United States, Brazil, and Mexico, with an
estimated number of people with diabetes of 10 million, and it is expected to increase to 16.7 million people in 2045. In
high-income countries, approximately 7%–12% of all people with diabetes are estimated to have type 1 diabetes, 87%–
91% are estimated to have type 2 diabetes, and 1%–3% are estimated to have other types of diabetes.[1] The prevalence
of DM is based on a doctor’s diagnosis in the population older than or equal to 15 years in Daerah Khusus Ibukota (DKI)
special capital district Jakarta, occupying the highest position of all provinces in Indonesia.[2]
Poor glycemic control is a significant contributor to the high rates of morbidity and mortality of patient with type 2
diabetes mellitus (T2DM).[3] One of the key factors related to glycemic control in patient with T2DM is medication
adherence (MA). Some studies reported that suboptimal glycemic control is found in patient with low MA.[4],[5]
Medication adherence (MA) is commonly used to define the level of compliance to which patients in following the
medication prescribed by their health providers. Poor adherence with medication will cause long-term complications that
increase morbidity and mortality and increase health costs.[6]
Poor MA is linked to nonpatient factors such as lack of integrated care in many health-care system and clinical inertia
among health-care professionals, patient demographic factors, critical patients belief about their medications, and
perceive patients burden regarding obtaining and taking their medications.[7] Some studies reported the complexity and
convenience of therapy associated with MA. Reduced tolerance to medication, frequency of medication more than twice
a day.[8]
Polypharmacy and/or polytherapy are prevalent in adults with diabetes, especially in individuals with chronic conditions.
Polypharmacy and/or polytherapy are one of the factors that influence the adherence of the patients to their medications.
Patients who take two drugs or less have a lower risk of lower MA than patients who take more than two drugs.[9] One
study in 2017 showed that of the 382 patients with T2DM who received polypharmacy, 57.1% had low adherence.[10]
Nevertheless, we hypothesized that other factors could affect MA and associate to the low MA in patients with T2DM in
Indonesia.
Therefore, the primary purpose of this study was to evaluate the MA of patients with T2DM who received polytherapy.
This study also aimed to identify factors that affect patient’s MA, which is represented by glycemic control of the
patients.
   Materials and Methods  
This was a cross-sectional study conducted in seven community health centers (CHC) in Jakarta, Indonesia, from
February 2019 to July 2019. The ethical approval for this study was obtained from the ethics committee of the Faculty of
Medicine of the University of Indonesia with number: 588/UN2.F1/ETIK/PPM.00.02/2019.
The inclusion criteria of this study included patients with T2DM who were on at least two antidiabetics (ADs) and aged
older than or equal to 18 years, of both genders, could speak and understand Indonesian, patients who were on all type of
ADs, patients with T2DM with or without comorbidities, patients who were followed up at the site in at least two visits
over a minimum period of 6 month. Meanwhile, patients with T2DM who were pregnant, patients who were on dietary
control alone, or had intellectual or cognitive impairment as stated in their medical record were excluded from this study.
Data were collected concurrently where potential subjects were screened by the trained research assistants and health
worker in the CHC for enrollment eligibility into this study. They were recruited on a monthly gathering of the Chronic
Disease Management Program (PROLANIS) in each CHC. Patients who met the requirements were asked to be the study
subject by signing a participation agreement or informed consent and given information in advance. A structured
questionnaire to obtain factors, which potentially affected MA such as sociodemographic (age, gender, education, and
occupation) and clinical characteristics (duration of T2DM, other chronic diseases, complication, number of ADs, and
regular daily drug), was given to patients, and then blood was taken to measure HbA1C level by trained health workers
who were responsible in each CHC.
The data collected were recapitulated and analyzed. A univariate analysis was carried out to measure the frequency of
each characteristic. MA assessment was based on the results of HbA1C examination with a controlled blood glucose
(HbA1C) level greater than or equal to 7%, indicated as low MA and vice versa.[11] The Kolmogorov–Smirnov test was
performed to measure the normality of the data. A P value >0.05 was considered statistically significant, which means
that the data were nonparametric. The univariate analysis with the Mann–Whitney U test was carried out on numerical
data that were not normally distributed, whereas for categorical data that were not normally distributed, chi-square test
and Fisher’s exact test were used. The data that were significantly related in the univariate analysis were used to perform
multivariate tests using multiple regression logistic tests, with the relationship reflected by odds ratios (ORs) (95%
confidence intervals [CIs]). A P value of 0.05 was considered statistically significant.
   Results  
A total of 143 patients with T2DM were enrolled in this study. The sociodemographic and clinical characteristics are
presented in [Table 1].
Table 1: Characteristics of the patients
Click here to view
Sociodemographic characteristics showed mean ± standard deviation (SD) age of patients as 59.53 ± 9.251 years, with a
slightly more dominance in elderly patients (≥60 years) (51.7%) and women (67.8%). Most of the patients were
categorized into moderate education (67.8%) and who did not work (78.3%).














than or equal to 5 years. Most of (76.2%) patients did not have nor had one other chronic disease such as hypertension,
hyperlipidemia, hyperuricemia, angina pectoris, and osteoporosis. As many as 14% of the patients experienced
complications in the form of diabetic ulcers and diabetic neuropathy. The use of AD in most patients with T2DM (95.1%)
was a combination of two ADs with the use of regular daily drug of up to three drugs.
Of all the characteristics, the duration of T2DM appeared significantly (P = 0.047) related to the level of the MA.
   Discussion  
We used the HbA1C level to represent the MA of the patients, because adherence is the key factor that is significantly
affecting glycemic factor of the patients.[10] This study found more than three-quarter (75.5%) of the patients with low
MA, which is shown by the HbA1C level more than or equal to 7% [Table 1]. This result is comparable to other studies in
other communities in Indonesia and other developing countries, which found low MA ranging from 52.7% to 79%.[4],[12]
Age did not show a significant relationship to the MA, with slight dominance in the adult patient who had low MA.
Meanwhile, female patients were found to have low MA. These observations did not correspond to some studies, which
also showed the adult and female patients tended to have low MA.[10],[13] Level of education and working activity did
not show any significance in the number of patients with low MA, which is also similar to a previous study.[10]
This study did not find the number of medications (AD or other) taken daily that affected MA; hence, it did not show an
association with low MA. Other studies also found the insufficiency of association between number of regular daily
drugs and low MA.[10],[14],[15],[16] Seven combinations of AD were used by the patients in the study, which were insulin
and acarbose; metformin and acarbose; metformin and glipalamide; metformin and gliquidone; metformin, gliquidone,
and acarbose; metformin and glimepiride; and metformin, glimepiride, and acarbose. Of all these combinations, the
combination of metformin and glimepiride reportedly had most patients with low MA. This result was not in accordance
with previous studies, which reported that the combination was more effective in glycemic control which should also
reflect their MA.[17]
This study underlined a significant association between the duration of T2DM and MA [Table 2]. Patients with T2DM
duration less than 5 years tend to have low MA (P = 0.015, OR = 1.206, 95% CI = 1.216–8.014). Another study had a
similar finding,[18] whereas there were other studies too, which found a lack of association between both.[19],[20]
Table 2: Logistic regression test results on factors influencing medication adherence
Click here to view
Limitations and strengths: Though this study measured the MA based on the reliable data of HbA1C assessment, it could
not identify the reason for low MA. However, this method is fast and convenient at a study site where the HbA1C is
regularly assessed. This study provided a better result on MA in glycemic control perspective in Indonesia, especially
Jakarta, due to the larger sample that covered seven community health centers in Jakarta.
Although our results did not show a relationship between polytherapy and low MA, health-care professionals must
continue to pay attention to patients receiving polytherapy and/or polypharmacy. This is because it is one of the risk
factors that affect MA. In this study, we found that the duration of T2DM was associated with a low MA, which
unexpectedly showed that patients who had T2DM for less than or equal to 5 years were more at risk of having a low
MA; therefore, further investigation of the factors affecting MA was needed in new patients with T2DM for less than 5
years.
   Conclusion  
This study shows a low increase in MA in patients with T2DM in Jakarta. This is important to be addressed by
supporting the growing awareness of adherence to antidiabetic among patients, for example, by giving regular education
to the patents. Although the polytherapy was found to be unrelated to MA, a surprising finding showed that patients who
experienced T2DM less than or equal to five years were prone to have low MA. Health care providers must continue to
strive to improve MA in T2DM patients. This can be done by providing counseling and/or any kind of education to
patients at each visit and correctly assessing the MA. In addition, improving the relationship between patients and health
workers by providing self-management guidelines, which can be done by patients, can also improve glycemic control and
health outcomes. As the implication of polytherapy on MA in patients with chronic disease was an intended problem we
wanted to identify in our study, we think pharmacy services such as therapeutic management are needed to optimize drug
use therefore the use of drugs can be more efficient. Pharmacist and other health workers can work together to not
prescribe or stop unnecessary drugs or drugs that cause problems.
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Original Article
Medication Adherence Assessment Among Patients with Type 2 Diabetes 
Mellitus Treated Polytherapy in Indonesian Community Health Center: A 
Cross Sectional-Study
Nora Wulandari, Maifitrianti Maifitrianti, Faridlatul Hasanah, Sri Atika, Risa Dini Putri
Background: Type 2 diabetes mellitus (T2DM) is a chronic disease where most 
of the patients usually need polytherapy. This could affect their medication 
adherence (MA). However, other complex factors may also associate with MA, 
which are important to identify. Aim: The purpose of this study was to evaluate 
the MA of patients with T2DM who received polytherapy and to identify other 
factors that can affect the MA. Materials and Methods: This was a cross-sectional 
study conducted in seven community health centers in Jakarta with HbA1C 
representing their MA level. Poor controlled blood glucose with Hemoglobin A1C 
(HbA1C) of ≥7% is indicated to have low MA. All characteristics were collected 
to identify factors that are potentially associated with low MA. The univariate 
analysis tests were used to analyze factors that potentially associate with low 
MA. Multiple logistic regression analysis was performed in the factors to find 
their relationship with low MA. Results: The study obtained 143 patients with a 
female dominance (67.8%) and mean ± standard deviation (SD) age of 59.53 ± 
9.251  years. Approximately 75.5% of the patients had low MA (HbA1C ≥ 7). 
Univariate analysis found that duration of T2DM significantly (P = 0.047) related 
to MA, where patients with T2DM of less than or equal to 5 years tended to have 
low MA. Logistic regression showed that patients with T2DM less than or equal 
to 5 years (P = 0.015, odds ratio = 1.206, 95% confidence interval = 1.216–8.014) 
were associated with low MA. Conclusion: Patients with the duration of T2DM 
less than or equal to 5 years surprisingly were susceptible to have low MA. Low 
MA was not affected by polytherapy.






D iabetes mellitus (DM) is a metabolic disorder with a maximum number of patients. In 2017, the 
prevalence of diabetics worldwide was 425 million, and 
it is estimated that in 2045, people with diabetes will 
reach 693 million. People with diabetes in Indonesia 
ranks sixth in the world along with China, India, the 
United States, Brazil, and Mexico, with an estimated 
number of people with diabetes of 10 million, and it 
is expected to increase to 16.7 million people in 2045. 
In high-income countries, approximately 7%–12% of 
all people with diabetes are estimated to have type  1 
diabetes, 87%–91% are estimated to have type 2 
diabetes, and 1%–3% are estimated to have other types 
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doctor’s diagnosis in the population older than or equal 
to 15 years in Daerah Khusus Ibukota (DKI) special 
capital district Jakarta, occupying the highest position 
of all provinces in Indonesia.[2]
Poor glycemic control is a significant contributor to 
the high rates of morbidity and mortality of patient 
with type 2 diabetes mellitus (T2DM).[3] One of the 
key factors related to glycemic control in patient with 
T2DM is medication adherence (MA). Some studies 
reported that suboptimal glycemic control is found in 
patient with low MA.[4,5] Medication adherence (MA) 
is commonly used to define the level of compliance to 
which patients in following the medication prescribed 
by their health providers. Poor adherence with 
medication will cause long-term complications that 
increase morbidity and mortality and increase health 
costs.[6]
Poor MA is linked to nonpatient factors such as 
lack of  integrated care in many health-care system 
and clinical inertia among health-care professionals, 
patient demographic factors, critical patients belief  
about their medications, and perceive patients burden 
regarding obtaining and taking their medications.[7] 
Some studies reported the complexity and convenience 
of  therapy associated with MA. Reduced tolerance to 
medication, frequency of  medication more than twice 
a day.[8]
Polypharmacy and/or polytherapy are prevalent in 
adults with diabetes, especially in individuals with 
chronic conditions. Polypharmacy and/or polytherapy 
are one of the factors that influence the adherence of 
the patients to their medications. Patients who take 
two drugs or less have a lower risk of lower MA than 
patients who take more than two drugs.[9] One study in 
2017 showed that of the 382 patients with T2DM who 
received polypharmacy, 57.1% had low adherence.[10] 
Nevertheless, we hypothesized that other factors could 
affect MA and associate to the low MA in patients with 
T2DM in Indonesia.
Therefore, the primary purpose of this study was to 
evaluate the MA of patients with T2DM who received 
polytherapy. This study also aimed to identify factors 
that affect patient’s MA, which is represented by 
glycemic control of the patients.
MAterIAls And Methods
This was a cross-sectional study conducted in seven 
community health centers (CHC) in Jakarta, Indonesia, 
from February 2019 to July 2019. The ethical approval 
for this study was obtained from the ethics committee of 
the Faculty of Medicine of the University of Indonesia 
with number: 588/UN2.F1/ETIK/PPM.00.02/2019.
The inclusion criteria of this study included patients 
with T2DM who were on at least two antidiabetics 
(ADs) and aged older than or equal to 18  years, of 
both genders, could speak and understand Indonesian, 
patients who were on all type of ADs, patients with 
T2DM with or without comorbidities, patients who 
were followed up at the site in at least two visits over 
a minimum period of 6  month. Meanwhile, patients 
with T2DM who were pregnant, patients who were on 
dietary control alone, or had intellectual or cognitive 
impairment as stated in their medical record were 
excluded from this study.
Data were collected concurrently where potential 
subjects were screened by the trained research assistants 
and health worker in the CHC for enrollment eligibility 
into this study. They were recruited on a monthly 
gathering of the Chronic Disease Management 
Program (PROLANIS) in each CHC. Patients who 
met the requirements were asked to be the study 
subject by signing a participation agreement or 
informed consent and given information in advance. 
A  structured questionnaire to obtain factors, which 
potentially affected MA such as sociodemographic 
(age, gender, education, and occupation) and clinical 
characteristics (duration of T2DM, other chronic 
diseases, complication, number of ADs, and regular 
daily drug), was given to patients, and then blood was 
taken to measure HbA
1C level by trained health workers 
who were responsible in each CHC.
The data collected were recapitulated and analyzed. 
A  univariate analysis was carried out to measure the 
frequency of each characteristic. MA assessment was 
based on the results of HbA1C examination with a 
controlled blood glucose (HbA1C) level greater than 
or equal to 7%, indicated as low MA and vice versa.[11] 
The Kolmogorov–Smirnov test was performed to 
measure the normality of the data. A  P value >0.05 
was considered statistically significant, which means 
that the data were nonparametric. The univariate 
analysis with the Mann–Whitney U test was carried out 
on numerical data that were not normally distributed, 
whereas for categorical data that were not normally 
distributed, chi-square test and Fisher’s exact test were 
used. The data that were significantly related in the 
univariate analysis were used to perform multivariate 
tests using multiple regression logistic tests, with 
the relationship reflected by odds ratios (ORs) (95% 
confidence intervals [CIs]). A  P value of 0.05 was 
considered statistically significant.
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results
A total of 143 patients with T2DM were enrolled 
in this study. The sociodemographic and clinical 
characteristics are presented in Table 1.
Sociodemographic characteristics showed mean ± 
standard deviation (SD) age of patients as 59.53  ± 
9.251 years, with a slightly more dominance in elderly 
patients (≥60  years) (51.7%) and women (67.8%). 
Most of the patients were categorized into moderate 
education (67.8%) and who did not work (78.3%).
On the basis of  its clinical characteristics, more than 
half  (69.3%) of  the patients had been diagnosed 
with T2DM for less than or equal to 5  years. 
Most of  (76.2%) patients did not have nor had 
one other chronic disease such as hypertension, 
hyperlipidemia, hyperuricemia, angina pectoris, 
and osteoporosis. As many as 14% of  the patients 
experienced complications in the form of  diabetic 
ulcers and diabetic neuropathy. The use of  AD in 
most patients with T2DM (95.1%) was a combination 
of  two ADs with the use of  regular daily drug of  up 
to three drugs.
Of all the characteristics, the duration of T2DM 
appeared significantly (P = 0.047) related to the level 
of the MA.
dIscussIon
We used the HbA1C level to represent the MA of the 
patients, because adherence is the key factor that is 
significantly affecting glycemic factor of the patients.[10] 
This study found more than three-quarter (75.5%) of 
the patients with low MA, which is shown by the HbA1C 
level more than or equal to 7% [Table 1]. This result is 
Table 1: Characteristics of the patients
Characteristics Total Adherent (HbA1C 
< 7%)
Low MA (HbA1C 
≥ 7%)
P value
Total 143 (100.0) 35 (24.5) 108 (75.5)  
Age (years)     
 Less than 60 years 69 (48.3) 14 (20.3) 55 (79.7)  
 60 years or more 74 (51.7) 21 (28.4) 53 (71.6) 0.353*
 Mean ± SD = 59.53 ± 9.251    
 Min–max = 37–85    
Gender    
 Male 46 (32.2) 12 (26.1) 34 (73.9) 0.920*
 Female 97 (67.8) 23 (23.7) 74 (76.3)  
Level of education    
 Basic 34 (23.8) 7 (20.6) 27 (79.4)  
 Moderate 96 (67.1) 23 (24.0) 73 (76.0) 0.434*
 High 13 (9.1) 5 (38.5) 8 (61.5)  
Occupation    
 Not working 112 (78.3) 26 (23.2) 86 (76.8) 0.505*
 Working 31 (21.7) 9 (29.0) 22 (71.0)  
Duration of T2DM    
 5 years or less 88 (61.5) 27 (30.7) 61 (69.3)  
 More than 5 years 55 (38.5) 8 (14.5) 47 (85.5) 0.047*
Other chronic diseases    
 None and one 109 (76.2) 28 (25.7) 81 (74.3)  
 Two and above 34 (23.8) 7 (20.6) 27 (79.4) 0.644*
Any complication    
 Yes 20 (14.0) 3 (15.0) 17 (85.0)  
 No 123 (86.0) 32 (26.0) 91 (74.0) 0.404***
Number of AD    
 Two 136 (95.1) 34 (25.0) 102 (75.0)  
 Three 7 (4.9) 1 (14.3) 6 (85.7) 0.522**
Number of regular daily drugs    
 Up to three 98 (68.5) 26 (26.5) 7 (73.5)  
 Four and more 45 (31.5) 9 (20.0) 3 (80.0) 0.130**
*Chi-square test, **Mann–Whitney U test, ***Fisher’s exact test
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comparable to other studies in other communities in 
Indonesia and other developing countries, which found 
low MA ranging from 52.7% to 79%.[4,12]
Age did not show a significant relationship to the MA, 
with slight dominance in the adult patient who had low 
MA. Meanwhile, female patients were found to have 
low MA. These observations did not correspond to 
some studies, which also showed the adult and female 
patients tended to have low MA.[10,13] Level of education 
and working activity did not show any significance in 
the number of patients with low MA, which is also 
similar to a previous study.[10]
This study did not find the number of medications (AD 
or other) taken daily that affected MA; hence, it did 
not show an association with low MA. Other studies 
also found the insufficiency of association between 
number of regular daily drugs and low MA.[10,14-16] 
Seven combinations of AD were used by the patients 
in the study, which were insulin and acarbose; 
metformin and acarbose; metformin and glipalamide; 
metformin and gliquidone; metformin, gliquidone, and 
acarbose; metformin and glimepiride; and metformin, 
glimepiride, and acarbose. Of all these combinations, 
the combination of metformin and glimepiride 
reportedly had most patients with low MA. This result 
was not in accordance with previous studies, which 
reported that the combination was more effective in 
glycemic control which should also reflect their MA.[17]
This study underlined a significant association between 
the duration of T2DM and MA [Table 2]. Patients 
with T2DM duration less than 5  years tend to have 
low MA (P  =  0.015, OR  =  1.206, 95% CI  =  1.216–
8.014). Another study had a similar finding,[18] whereas 
there were other studies too, which found a lack of 
association between both.[19,20]
Limitations and strengths: Though this study measured 
the MA based on the reliable data of HbA1C assessment, 
it could not identify the reason for low MA. However, 
this method is fast and convenient at a study site where 
the HbA1C is regularly assessed. This study provided a 
better result on MA in glycemic control perspective in 
Indonesia, especially Jakarta, due to the larger sample 
that covered seven community health centers in Jakarta.
Although our results did not show a relationship 
between polytherapy and low MA, health-care 
professionals must continue to pay attention to patients 
receiving polytherapy and/or polypharmacy. This is 
because it is one of the risk factors that affect MA. 
In this study, we found that the duration of T2DM 
was associated with a low MA, which unexpectedly 
showed that patients who had T2DM for less than or 
equal to 5 years were more at risk of having a low MA; 
therefore, further investigation of the factors affecting 
MA was needed in new patients with T2DM for less 
than 5 years.
conclusIon
This study shows a low increase in MA in patients 
with T2DM in Jakarta. This is important to be 
addressed by supporting the growing awareness 
of adherence to antidiabetic among patients, for 
example, by giving regular education to the patents. 
Although the polytherapy was found to be unrelated 
to MA, a surprising finding showed that patients who 
experienced T2DM less than or equal to five years were 
prone to have low MA. Health care providers must 
continue to strive to improve MA in T2DM patients. 
This can be done by providing counseling and/or 
any kind of education to patients at each visit and 
correctly assessing the MA. In addition, improving the 
relationship between patients and health workers by 
providing self-management guidelines, which can be 
done by patients, can also improve glycemic control and 
health outcomes. As the implication of polytherapy on 
MA in patients with chronic disease was an intended 
problem we wanted to identify in our study, we think 
pharmacy services such as therapeutic management are 
needed to optimize drug use therefore the use of drugs 
can be more efficient. Pharmacist and other health 
workers can work together to not prescribe or stop 
unnecessary drugs or drugs that cause problems.
Table 2: Logistic regression test results on factors influencing medication adherence
Characteristics Low MA (OR, 95% CI)* P value
Age (years) 1.907 (0.789–4.606) 0.152
Gender 0.927 (0.352–2.437) 0.877
Level of education 0.575 (0.268–1.236) 0.156
Occupation 1.807 (0.604–5.410) 0.290
Other chronic diseases 1.586 (0.462–5.448) 0.464
Number of AD 2.455 (0.237–25.375) 0.451
Duration of T2DM 3.173 (1.206–8.014) 0.015
Number of regular daily drugs 1.181 (0.387–3.602) 0.743
*Multiple logistic regression
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